Disseminated intravascular coagulation complicating diagnosis of ROS1‐mutant non‐small cell lung cancer: A case report and literature review

• Main Authors: Rachel Woodford, Michel Lu, Nadine Beydoun, Wendy Cooper, Qin Liu, Jodi Lynch, Lawrence Kasherman
• Format: Article
• Language: English
• Published: Wiley 2021-09-01
• Series: Thoracic Cancer
• Subjects: disseminated intravascular coagulation; non‐small‐cell lung cancer; oncogene addiction; paraneoplastic syndrome; ROS1 mutation
• Online Access: https://doi.org/10.1111/1759-7714.14071

Abstract Disseminated intravascular coagulation (DIC) is a rare paraneoplastic complication in advanced solid malignancies, with success of treatment and survival dependent on treatment of the underlying malignancy. Best estimates suggest an incidence of 1.6–6.8% in cancer, with risk factors being advanced disease, older age, and adenocarcinoma, especially of lung origin. Few cases, however, have reported on an association between DIC and oncogene‐addicted lung cancers, especially those containing ROS proto‐oncogene 1 (ROS1) mutations, however precedent exists to suggest increased prothrombotic rates in tumors harboring this mutation. We present a young woman with ROS1‐mutant non‐small‐cell lung cancer who presented in DIC and subsequently developed complications of both hemorrhage and thrombosis. Following initiation of targeted treatment, rapid resolution of laboratory coagulation derangement was observed and clinical improvement quickly followed. This event underscores the need for rapid evaluation of lung molecular panels and the dramatic resolution of life‐threatening illness that can occur with institution of appropriate therapy. This case contributes to growing evidence for a possible underlying link between oncogene addicted tumors and abnormalities of coagulation.